Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 6,687 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) CEO Patrick Miles sold 6,687 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares of the company's stock, valued at approximately $66,020,580. This represents a 0.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alphatec Price Performance

Shares of Alphatec stock traded up $0.29 during mid-day trading on Thursday, reaching $11.67. 1,276,798 shares of the stock traded hands, compared to its average volume of 1,852,914. The stock has a market capitalization of $1.66 billion, a PE ratio of -9.12 and a beta of 1.41. The business has a 50-day moving average of $9.80 and a 200 day moving average of $8.08. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its stake in Alphatec by 65.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company's stock worth $33,365,000 after purchasing an additional 1,260,137 shares during the last quarter. State Street Corp boosted its position in Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after acquiring an additional 287,350 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Alphatec by 11.3% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company's stock worth $16,280,000 after acquiring an additional 297,850 shares during the last quarter. Fred Alger Management LLC grew its stake in Alphatec by 0.8% during the 2nd quarter. Fred Alger Management LLC now owns 2,638,303 shares of the medical technology company's stock valued at $27,570,000 after acquiring an additional 21,078 shares in the last quarter. Finally, Royce & Associates LP raised its holdings in Alphatec by 15.9% in the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company's stock valued at $6,740,000 after acquiring an additional 165,954 shares during the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Tuesday, January 14th. Barclays upped their price target on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Wednesday. Finally, Needham & Company LLC raised their price objective on Alphatec from $13.00 to $16.00 and gave the company a "buy" rating in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.